1384071-99-1

AD80, a multi-kinase inhibitor, is more active against human RET (c-RET), BRAF, S6K, and SRC, but less active against mTOR than AD57 or AD58. Its IC50 value for RET (c-RET) is 4 nM.

AD80 is a potent RET inhibitor with favorable pharmacokinetic profile in clinically relevant RET fusion-driven tumor models. In patient-derived xenograft species, AD80 effectively reduced RET-rearranged tumor size.

Target	Value
Raf (Cell-free)
Src < br/> (Cell-free)
S6 Kinase (Cell-free)
RET V804M (Cell-free assay)	0.4 nM
RET V804L (Cell-free assay)	0.6 nM

Store at -20°C